Clinical Trial Update: Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial assessing Dipeptidyl Peptidase-4 inhibitors for Type 1 diabetes and non-alcoholic steatohepatitis (NASH) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis
• Type 1 Diabetes Mellitus

Snippet

Sponsor: Ain Shams University | Conditions: Diabetes Mellitus, Type 1, NASH | Phase 3 | Status: COMPLETED